Futura Medical plc has disclosed its total issued share capital, which stands at 301,863,641 Ordinary Shares, with no shares held in treasury. This figure represents the total number of voting rights in the company, as per the FCA's Disclosure and Transparency Rules. Shareholders can use this as the denominator for determining if they are required to notify any changes in their interest in the share capital of the Company.

Futura Medical plc is a pharmaceutical company specializing in the development of innovative sexual health products. Their lead product, Eroxon, is a topically delivered gel formulation designed for the treatment of Erectile Dysfunction (ED). Eroxon is a unique over-the-counter topical gel that has been clinically proven to help men achieve an erection in just ten minutes, addressing significant unmet needs in the ED market.

The company emphasizes the prevalence of ED, affecting 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses occurring in men under 40. Futura Medical plc's core strength lies in its research, development, and commercialization of topically delivered gel formulations in sexual health products, with Eroxon being a highly differentiated product in the ED treatment market.